
|Articles|April 11, 2008
Inhalable insulin prescribing information revised to include lung malignancy occurrence
Pfizer revises package insert after reports of lung cancer in patients receiving their inhaled insulin.
Advertisement
Pfizer has issued letters to both healthcare professionals and patients to inform them of six reported cases of newly diagnosed primary lung malignancy during clinical trials in patients using their insulin human [rDNA origin] inhalation powder (
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide
2
How PBMs Legally Challenged Arkansas’ Pharmacy Ownership Law | NCPA 2025
3
Pioglitazone Added to Metformin, Dapagliflozin Lowers Glucose for Patients With Diabetes
4
Pharmacists Can Improve Clinical Services, Patient Outcomes as Payer Models Evolve | NCPA 2025
5

























































































































































